论文部分内容阅读
目的探讨低分子肝素钙雾化吸入对慢性肺原性心脏病(肺心病)的治疗价值。方法90例肺心病患者随机分为治疗组与对照组,对照组给予常规治疗,治疗组在常规治疗的基础上应用低分子肝素钙雾化吸入,100IU/kg,q12h,疗程7d。治疗前后监测血液流变学指标、动脉血气分析、血液学指标,评估疗效。结果治疗7d后治疗组血液流变学指标明显改善,PaO2明显上升,PaCO2明显下降,血液学指标变化不明显。治疗组临床总效率896%,明显高于对照组(666%)(P<005)。结论低分子肝素钙雾化吸入可明显改善肺心病患者的血液粘稠度和肺通气功能,给药方便,安全有效,不需血液监测,无局部出血。
Objective To investigate the therapeutic value of low molecular weight heparin calcium inhalation on chronic pulmonary heart disease (pulmonary heart disease). Methods Ninety patients with pulmonary heart disease were randomly divided into treatment group and control group. The control group was given routine treatment. The treatment group was given low molecular heparin calcium inhalation, 100IU / kg, q12h for 7 days on the basis of routine treatment. Before and after treatment monitoring of blood rheology indicators, arterial blood gas analysis, hematological indicators, to assess the efficacy. Results After 7 days of treatment, the indexes of hemorheology in treatment group were significantly improved, PaO2 significantly increased, PaCO2 significantly decreased, and the hematological indexes did not change significantly. The total clinical efficiency of the treatment group was 896%, which was significantly higher than that of the control group (666%) (P <005). Conclusion Low molecular weight heparin calcium inhalation can significantly improve the blood viscosity and pulmonary ventilation in patients with pulmonary heart disease, convenient administration, safe and effective, without blood monitoring, no local bleeding.